Orphan drug market set to climb above $200B: Report

Fierce Pharma ------ Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as biopharma companies increasingly focus on meds to treat a variety of rare diseases. Sales for the super-pricey drug class will nearly double—again—by 2022 to $209 billion, according to a new industry analysis. In its new World Preview report, life science commercial intelligence firm Evaluate projects orphan drug sales will represent 32% of pharma’s total growth through 2022. After reaching $115 billion in sales last year, the class will add $95 billion more by 2022, according to the analysts. As Evaluate’s report notes, the trend comes as drugmakers increasingly look to rare disease meds because they can address a greater unmet need and offer a “more compelling market access value proposition.” Further, drugmakers can win development incentives for advancing meds to treat rare diseases. To learn more click on the picture below to read the article.